BLS Pharmaceuticals Limited (ASX: BLS) has announced record audited financial results for the year ended 30 June 2026 (FY26), driven by substantial international platform expansion. The Australian pharmaceutical company, focused on the manufacture, development and commercialisation of regulated therapeutic products and active pharmaceutical ingredients, operates a GMP-licensed manufacturing, import, export and distribution platform spanning medicinal cannabis, psychedelic medicines and other controlled pharmaceutical products. The company reported revenue of $74.2 million, a 161% increase on FY25, landing at the top end of its FY26 guidance. Adjusted EBITDA surged by 171% to $19.0 million, achieving an adjusted EBITDA margin of 26%.
Net profit after tax reached $15.4 million, a significant rise from $4.9 million in the previous financial year. BLS also generated a net operating cash flow of $5.4 million, concluding FY26 with $13.3 million in cash reserves. Operationally, FY26 marked a pivotal year of transformation, as the company secured a two-year, $50 million pharmaceutical supply agreement with ADREXpharma in Germany, which includes a minimum purchase commitment of $25 million in the first 12 months. Manufacturing also commenced for Aurora Cannabis, further expanding its commercial reach.
The company established its presence in Latin America with its first commercial supply into Costa Rica and continued the development of its Good Manufacturing Practice (GMP) pharmaceutical manufacturing facility in Scotland, enhancing its international manufacturing footprint. Looking ahead to FY27, BLS Pharmaceuticals aims to leverage its established Australian operating base, substantial manufacturing capacity, and major international supply agreements. The company remains focused on executing existing contracts, optimising its Australian manufacturing platform, expanding into new international markets, and completing its UK production site to deliver sustained value.
